Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Interview: German Merck Set For Big "Leap" In India

Executive Summary

Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.


Related Content

Merck KgaA-P&G Deal: Complex In Some Emerging Markets But No ‘Dis-Synergies’
Resilient US Rebif, Gonal-f Q2 Sales Allow German Merck To Up Forecast
German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space
Indian Avastin Biosimilar Arrives Amid Roche's Charges
Merck KGaA's Cladribine Revival Smacks Of Desperation
INTERVIEW: Merck Serono CEO On Growing In A Slowing China
Merck Serono pairs up with Lupin for emerging markets


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts